DK0813423T3 - Præparat til forebyggelse af osteolysis og metastase - Google Patents
Præparat til forebyggelse af osteolysis og metastaseInfo
- Publication number
- DK0813423T3 DK0813423T3 DK96903630T DK96903630T DK0813423T3 DK 0813423 T3 DK0813423 T3 DK 0813423T3 DK 96903630 T DK96903630 T DK 96903630T DK 96903630 T DK96903630 T DK 96903630T DK 0813423 T3 DK0813423 T3 DK 0813423T3
- Authority
- DK
- Denmark
- Prior art keywords
- antibody
- bone
- pthrp
- bisphosphonate
- sequelae
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
- A61K31/36—Compounds containing methylenedioxyphenyl groups, e.g. sesamin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/241—Tumor Necrosis Factors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Oncology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/376,359 US5626845A (en) | 1995-01-23 | 1995-01-23 | Method to ameliorate osteolysis and metastasis |
US08/386,361 US5993817A (en) | 1995-01-23 | 1995-02-09 | Method to ameliorate osteolysis and metastasis |
US48108895A | 1995-06-06 | 1995-06-06 | |
PCT/US1996/000895 WO1996022790A1 (en) | 1995-01-23 | 1996-01-23 | Composition to ameliorate osteolysis and metastasis |
Publications (1)
Publication Number | Publication Date |
---|---|
DK0813423T3 true DK0813423T3 (da) | 2002-07-22 |
Family
ID=27409296
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK96903630T DK0813423T3 (da) | 1995-01-23 | 1996-01-23 | Præparat til forebyggelse af osteolysis og metastase |
Country Status (12)
Country | Link |
---|---|
US (1) | US20050244414A1 (de) |
EP (1) | EP0813423B1 (de) |
JP (1) | JP4231106B2 (de) |
KR (1) | KR100528604B1 (de) |
AT (1) | ATE219945T1 (de) |
AU (1) | AU703222B2 (de) |
CA (1) | CA2210484C (de) |
DE (1) | DE69622157T2 (de) |
DK (1) | DK0813423T3 (de) |
ES (1) | ES2179929T3 (de) |
PT (1) | PT813423E (de) |
WO (1) | WO1996022790A1 (de) |
Families Citing this family (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5914233A (en) * | 1996-08-23 | 1999-06-22 | Osteo Screen | Screening assay for the identification of agents which alter expression of PTH-rP |
CN1817906B (zh) * | 1996-09-26 | 2011-08-10 | 中外制药株式会社 | 抗人副甲状腺激素相关蛋白的抗体 |
AU744146B2 (en) * | 1996-09-26 | 2002-02-14 | Chugai Seiyaku Kabushiki Kaisha | Antibody against human parathormone related peptides |
AU2003203622B2 (en) * | 1997-05-15 | 2006-12-21 | Chugai Seiyaku Kabushiki Kaisha | Cachexia remedy |
DE69837707T2 (de) * | 1997-05-15 | 2008-01-10 | Chugai Seiyaku K.K. | Heilmittel für kachexie |
DE19828450A1 (de) * | 1998-06-26 | 1999-12-30 | Hassan Jomaa | Bisphosphonsäuren und deren Derivate enthaltende Arzneimittel zur Prophylaxe und zur Behandlung von Autoimmunkrankheiten sowie von Allergien |
JP5232818B2 (ja) * | 1998-08-06 | 2013-07-10 | 達也 沢村 | 酸化ldl受容体に対する抗体を含んでなる医薬組成物 |
TWI255718B (en) | 1999-07-02 | 2006-06-01 | Chugai Pharmaceutical Co Ltd | Ameliorative agent for low vasopressin concentration |
AU2228901A (en) * | 1999-12-28 | 2001-07-09 | Chugai Seiyaku Kabushiki Kaisha | Stable antibody compositions and injection preparations |
US20030049211A1 (en) * | 2000-01-25 | 2003-03-13 | Atsuhiko Kato | Remedies and preventives for dental diseases |
ATE420661T1 (de) † | 2000-04-28 | 2009-01-15 | Chugai Pharmaceutical Co Ltd | Zellproliferation-inhibitoren |
JP2003021631A (ja) * | 2001-05-10 | 2003-01-24 | Chugai Pharmaceut Co Ltd | 骨転移抑制剤のスクリーニング方法 |
FR2841788B1 (fr) | 2002-07-05 | 2006-01-27 | Univ Pasteur | Utilisation d'antagonistes de la pthrp pour traiter le carcinome a cellules renales |
WO2004027420A1 (en) * | 2002-09-18 | 2004-04-01 | London Health Sciences Centre Research Inc. | Method of diagnosing osteolysis |
GB0303337D0 (en) | 2003-02-13 | 2003-03-19 | Celltech R&D Ltd | Biological products |
EP1557176A1 (de) * | 2004-01-26 | 2005-07-27 | Ferring B.V. | Behandlung von Knochen-Metastasen mit Hilfe von PTH-Rezeptor-Agonisten |
US9688718B2 (en) | 2008-01-11 | 2017-06-27 | Lawrence Livermore National Security, Llc | Nanolipoprotein particles comprising hydrogenases and related products, methods and systems |
US20090203549A1 (en) * | 2008-02-07 | 2009-08-13 | Hoeprich Jr Paul D | Functionalized platform for arrays configured for optical detection of targets and related arrays, methods and systems |
US9303273B2 (en) | 2008-05-09 | 2016-04-05 | Lawrence Livermore National Security, Llc | Nanolipoprotein particles comprising a natural rubber biosynthetic enzyme complex and related products, methods and systems |
ES2598006T3 (es) * | 2009-04-24 | 2017-01-24 | Vanderbilt University | Anticuerpos anti-TGF-beta para la inducción del crecimiento óseo |
US8906610B2 (en) * | 2010-02-08 | 2014-12-09 | The Regents Of The University Of California | Using phylogenetic probes for quantification of stable isotope labeling and microbial community analysis |
US9644038B2 (en) | 2011-12-21 | 2017-05-09 | The Regents Of The University Of California | Apolipoprotein nanodiscs with telodendrimer |
US20150023920A1 (en) * | 2012-03-29 | 2015-01-22 | Drexel University | Novel compositions and methods for preventing or treating cancer metastasis |
WO2016049061A1 (en) | 2014-09-22 | 2016-03-31 | Lawrence Livermore National Security, Llc | Electrochemical flow-cell for hydrogen production and nicotinamide co-factor dependent target reduction, and related methods and systems |
RU2609871C1 (ru) * | 2015-08-10 | 2017-02-06 | Федеральное бюджетное учреждение науки "Государственный научный центр вирусологии и биотехнологии "Вектор" Федеральной службы по надзору в сфере защиты прав потребителей и благополучия человека (ФБУН ГНЦ ВБ "Вектор" Роспотребнадзора) | Противоопухолевое средство |
US11279749B2 (en) | 2015-09-11 | 2022-03-22 | Lawrence Livermore National Security, Llc | Synthetic apolipoproteins, and related compositions methods and systems for nanolipoprotein particles formation |
US11207422B2 (en) | 2017-05-02 | 2021-12-28 | Lawrence Livermore National Security, Llc | MOMP telonanoparticles, and related compositions, methods and systems |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0092004B1 (de) * | 1982-04-20 | 1985-10-30 | Teijin Limited | Vitamin-D3-Derivate, Verfahren zu ihrer Herstellung und die diese Derivate enthaltenden Antigene die für die Herstellung von Antikörpern zu immunochemischen Testverfahren gebraucht werden und die daraus bereiteten Antikörper |
FR2556739A1 (fr) * | 1983-12-19 | 1985-06-21 | Pasteur Institut | Lignees cellulaires secretant des anticorps monoclonaux contre la pg e2, leur preparation, les anticorps obtenus et leur application |
IL75318A (en) * | 1984-05-31 | 1994-08-26 | Genentech Inc | Recombinant human memotoxin and methods for its recombinant production |
WO1988000596A1 (en) * | 1986-07-18 | 1988-01-28 | The University Of Melbourne | A PROTEIN ACTIVE IN HUMORAL HYPERCALCEMIA OF MALIGNANCY-PTHrP |
DK590387A (da) * | 1986-11-13 | 1988-05-14 | Otsuka Pharma Co Ltd | Antistoffer mod interleukin-1 |
US5312810A (en) * | 1987-05-20 | 1994-05-17 | The University Of Melbourne | Method and compositions for making ACSF and ACSF antagonists |
DE3804686A1 (de) * | 1988-02-15 | 1989-08-24 | Henkel Kgaa | Arzneimittel mit einer kombination von cytostatika bzw. hormontherapeutika und phosphonoderivaten |
US5183657A (en) * | 1988-03-11 | 1993-02-02 | Celltech Limited | Antibodies for use in antilymphocyte antibody therapy |
US5114843A (en) * | 1988-05-09 | 1992-05-19 | Merck & Co., Inc. | Humoral hypercalcemic factor antagonists |
EP0355067A1 (de) * | 1988-08-19 | 1990-02-21 | Celltech Limited | Arzneimittel gegen bösartige Gewebeneubildung |
SG43205A1 (en) * | 1988-12-19 | 1997-10-17 | American Cyanamid Co | A method for the treatment of endotoxic shock in a mammal |
US5530101A (en) * | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US5217896A (en) * | 1988-12-30 | 1993-06-08 | Oncogene Science, Inc. | Monoclonal antibodies recognizing parathyroid hormone-like protein |
JPH04228089A (ja) * | 1990-05-15 | 1992-08-18 | Kanegafuchi Chem Ind Co Ltd | 高カルシウム血症治療・予防剤 |
GB9109645D0 (en) * | 1991-05-03 | 1991-06-26 | Celltech Ltd | Recombinant antibodies |
US5334380A (en) * | 1991-09-27 | 1994-08-02 | Board Of Regents, The University Of Texas System | Anti-endotoxin, interleukin-1 receptor antagonist and anti-tumor necrosis factor antibody with arginine-free formulations for the treatment of hypotension |
US5403829A (en) * | 1993-03-24 | 1995-04-04 | Leiras Oy | Use of bisphosphonates in endo-osteal bone surgery |
WO1995001997A1 (en) * | 1993-07-09 | 1995-01-19 | Smithkline Beecham Corporation | RECOMBINANT AND HUMANIZED IL-1β ANTIBODIES FOR TREATMENT OF IL-1 MEDIATED INFLAMMATORY DISORDERS IN MAN |
EP0659766A1 (de) * | 1993-11-23 | 1995-06-28 | Schering-Plough | Menschliche Monoklonalantikörper gegen menschliche Cytokine und Verfahren zur Herstellung dieser Antikörper |
US5626845A (en) * | 1995-01-23 | 1997-05-06 | Xenotech Incorporated | Method to ameliorate osteolysis and metastasis |
-
1996
- 1996-01-23 JP JP52297596A patent/JP4231106B2/ja not_active Expired - Fee Related
- 1996-01-23 DK DK96903630T patent/DK0813423T3/da active
- 1996-01-23 KR KR1019970704977A patent/KR100528604B1/ko not_active IP Right Cessation
- 1996-01-23 PT PT96903630T patent/PT813423E/pt unknown
- 1996-01-23 WO PCT/US1996/000895 patent/WO1996022790A1/en active IP Right Grant
- 1996-01-23 CA CA2210484A patent/CA2210484C/en not_active Expired - Fee Related
- 1996-01-23 DE DE69622157T patent/DE69622157T2/de not_active Expired - Lifetime
- 1996-01-23 AU AU47645/96A patent/AU703222B2/en not_active Ceased
- 1996-01-23 AT AT96903630T patent/ATE219945T1/de active
- 1996-01-23 EP EP96903630A patent/EP0813423B1/de not_active Expired - Lifetime
- 1996-01-23 ES ES96903630T patent/ES2179929T3/es not_active Expired - Lifetime
-
2005
- 2005-04-18 US US11/109,470 patent/US20050244414A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
EP0813423A1 (de) | 1997-12-29 |
US20050244414A1 (en) | 2005-11-03 |
EP0813423A4 (de) | 1998-04-22 |
JPH10512885A (ja) | 1998-12-08 |
AU4764596A (en) | 1996-08-14 |
EP0813423B1 (de) | 2002-07-03 |
DE69622157T2 (de) | 2003-03-13 |
PT813423E (pt) | 2002-11-29 |
ES2179929T3 (es) | 2003-02-01 |
KR19980701585A (ko) | 1998-05-15 |
CA2210484A1 (en) | 1996-08-01 |
KR100528604B1 (ko) | 2006-03-16 |
DE69622157D1 (de) | 2002-08-08 |
WO1996022790A1 (en) | 1996-08-01 |
JP4231106B2 (ja) | 2009-02-25 |
ATE219945T1 (de) | 2002-07-15 |
AU703222B2 (en) | 1999-03-18 |
CA2210484C (en) | 2012-12-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK0813423T3 (da) | Præparat til forebyggelse af osteolysis og metastase | |
DE60220403D1 (de) | Zusammensetzung zur unterdrückung von magensäure | |
EA200000718A1 (ru) | Композиции целекоксиба | |
KR930003912A (ko) | 울혈성 심장 마비 치료법 | |
RU2008103617A (ru) | Бисфосфоновые кислоты, предназначенные для лечения и профилактики остеопороза | |
CZ20014289A3 (cs) | Nové pouľití sloučenin jako antibakteriálních činidel | |
CY1115707T1 (el) | Στερεα σταθεροποιημενα θεραπευτικα συστηματα ταχειας και/ή τροποποιημενης απελευθερωσης για τη χορηγηση απο του στοματος υγρων δραστικων ουσιων, εκδοχων ή τροφιμων | |
GB9900334D0 (en) | Tricylic vascular damaging agents | |
BR9510168A (pt) | Composto poliaminoácido composição forma unitária de dosagem e método par epreparar uma composição | |
ES2162615T3 (es) | Metodo para tratar o prevenir diabetes de tipo 1 mediante la administracion oral de insulina. | |
DE69724451D1 (de) | Kombinationtherapie mit einem tnf-bindendem protein zür behandlung von durch tnf verursachten erkrangungen | |
RU94046316A (ru) | Применение высокоэффективных фосфонатов при изготовлении лекарственных средств для лечения остеопороза | |
HUP0300421A2 (hu) | Kezelési eljárás ligand-immunogén konjugátumok felhasználásával | |
KR970705553A (ko) | 디히드로벤조푸란, 및 항염증 약물로서 유용한 관련 화합물(dihydrobenzofuran and related compounds useful as anti-inflammatory agents) | |
NO170114B (no) | Elektrisk kontaktklemme | |
RU2002134754A (ru) | Аналоги жирных кислот для лечения рака | |
ATE268174T1 (de) | Sibutramin und orlistat enthaltende pharmazeutische zusammensetzungen | |
Strum | Ranitidine | |
KR970061249A (ko) | 골다공증을 치료 또는 방지하기 위한 조성물 | |
RU94046106A (ru) | Содержащие четвертичный азот фосфонатные соединения для лечения анормального кальциевого и фосфатного метаболизма, а также профилактики и лечения зубных налетов и зубных камней, фармацевтические композиции, способ лечения | |
Funayama et al. | Elevation of histidine decarboxylase activity in the mandible of mice by Prevotella intermedia lipopolysaccharide and its augmentation by an aminobisphosphonate | |
ATE13488T1 (de) | Gallium-chlorid, ein neues antikrebsmittel. | |
DE69926357D1 (de) | Vorbereitung eines medikaments zur behandlung von refluxösophagitis | |
RU2350351C2 (ru) | Композиции и лекарственные формы на основе гастрина, методы применения и получения | |
KR910007526A (ko) | 인터류킨-1 생합성 억제제로의 3-치화된-2-옥신돌 유도체 |